Slingshot members are tracking this event:
ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA) in Acute Myeloid Leukemia
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
The open-label, randomized, multi-center clinical trial, which is being conducted at more than 20 sites in Europe, has completed enrollment of a total of 123 patients and is on track for reporting of primary data in the second half of 2017. Patients enrolled in the trial are over the age of 65, newly-diagnosed with AML, and unable to receive intensive chemotherapy. The primary endpoint is overall survival (OS) at one year.
Slingshot Insights Explained
Aug 29, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Graspa, Phase 2b Trial, Eryaspase, Acute Myeloid Leukemia, Ery-asp